What one share of Cypherpunk Technologies holds
We were incorporated in the state of Delaware on January 3, 2011. Our wholly owned subsidiaries as of December 31, 2025 include HealthCare Pharmaceuticals Pty Ltd. (“HCP Australia”), Leap Securities Corp., Flame Biosciences LLC, and Leap Therapeutics, Inc.
Cypherpunk Technologies’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.01 |
|---|---|
| Cash and investments | $0.07 |
| Book value | $1.29 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$33.13 | $0.07 | −$24.16 | — | $9.00 |
| 2018 | — | −$21.11 | — | — | — | $6.24 |
| 2019 | — | −$14.73 | $0.04 | −$11.96 | — | −$0.72 |
| 2020 | $0.25 | −$6.34 | — | — | — | $7.82 |
| 2021 | $0.17 | −$4.73 | — | — | — | $18.08 |
| 2022 | — | −$4.82 | — | — | — | $5.94 |
| 2023 | — | −$3.98 | — | — | — | $2.35 |
| 2024 | — | −$1.81 | — | — | — | $0.91 |
| 2025 | — | $0.07 | — | — | — | $1.83 |
Common questions about Cypherpunk Technologies
How much does one share of Cypherpunk Technologies earn?
Over the last 12 months, Cypherpunk Technologies lost $0.01 for each share.
Does Cypherpunk Technologies pay a dividend?
Cypherpunk Technologies didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Cypherpunk Technologies’s book value per share?
Cypherpunk Technologies’s book value is $1.29 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Cypherpunk Technologies have?
Each share of Cypherpunk Technologies has $0.07 of cash and investments, as of June 30, 2026.
Has Cypherpunk Technologies bought back shares?
Cypherpunk Technologies’s share count rose about 7591% from 2017 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.